HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists qualify for weight loss when BMI is ≥27 with weight-related comorbidities or ≥30 regardless of comorbidities. Medical history, metabolic markers, and cardiovascular status are central to eligibility—not just scale weight.

PlexusDx emphasizes precision wellness: understanding your individual biomarker profile and genetic predispositions in peptide pathways can strengthen the conversation with your provider about whether GLP-1 therapy aligns with your specific health context.

BMI and Medical Comorbidity Thresholds

The FDA-approved indication for GLP-1 weight loss therapy requires a BMI of 27 kg/m² or higher with weight-related conditions (hypertension, dyslipidemia, type 2 diabetes) or a BMI of 30 kg/m² or higher without comorbidities. BMI alone is not sufficient; medical history shapes eligibility.

Weight-related comorbidities include cardiovascular disease, prediabetes, type 2 diabetes, hypertension, and dyslipidemia. Your provider will review your full metabolic profile to determine whether GLP-1 therapy addresses your specific health risks and supports your treatment goals.

Key Clinical and Metabolic Factors for Provider Evaluation

Beyond BMI, your provider evaluates glucose metabolism, lipid levels, blood pressure, and cardiovascular history. These biomarkers help determine GLP-1 suitability and inform dosing strategy. A comprehensive metabolic panel is often the foundation for eligibility assessment.

Clinical Factor Why It Matters for GLP-1 Eligibility
Fasting glucose or HbA1c Indicates insulin resistance and diabetes risk; GLP-1 improves glycemic control and may reduce cardiovascular risk in prediabetes or type 2 diabetes.
Blood pressure GLP-1 therapy may support blood pressure reduction; baseline hypertension is a qualifying comorbidity and helps determine treatment urgency.
Lipid profile (LDL, triglycerides) Dyslipidemia is a common weight-related comorbidity; GLP-1 can improve triglyceride levels and may reduce cardiovascular event risk.
Cardiovascular history Prior MI, stroke, or established CVD may increase urgency for GLP-1 therapy; recent GLP-1 trials show cardiovascular benefit in high-risk populations.
Kidney function (eGFR) GLP-1 is generally safe in mild-to-moderate renal impairment; baseline kidney function guides dosing and monitoring decisions.
Liver function Baseline liver assessment helps rule out contraindications; no hepatic dose adjustment typically needed for GLP-1 agents.

Genetic Predispositions in Peptide Pathways and Individual Response

Genetic variants in GLP-1 receptor, GIPR, FTO, and MC4R genes may influence appetite regulation and weight response patterns. These predispositions do not predict exact medication efficacy but can help providers contextualize why some individuals respond differently to GLP-1 therapy.

The Precision Peptide Genetic Test identifies variants associated with peptide pathway function—such as GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609. Understanding your genetic profile may support a more informed conversation with your provider about treatment expectations and personalization.

Medical History and Safety Considerations

Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Relative cautions include severe gastrointestinal disease, pancreatitis history, and diabetic retinopathy. Your provider must assess these before initiating therapy.

Current medications, injectable therapy tolerance, and compliance capacity also influence eligibility. If you have a history of allergic reactions to GLP-1 agents, pancreatitis, or severe gastroparesis, discuss these thoroughly with your provider before starting treatment. Ongoing monitoring ensures safety throughout therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your genetic background influences peptide pathway function and appetite regulation. Results should be interpreted with a qualified healthcare provider to inform personalized treatment decisions—genetic predispositions do not guarantee exact medication response.

The test identifies variants in genes like GLP1R, GIPR, FTO, and MC4R that relate to GLP-1 signaling and metabolic function. Understanding these predispositions can support a more nuanced conversation with your provider about treatment expectations and whether compounded GLP-1 or GLP-1/GIPR dual therapy may align with your individual profile.

By combining your clinical biomarkers (glucose, lipids, blood pressure, kidney function) with genetic context, you and your provider can make a more informed decision about GLP-1 suitability. PlexusDx's compounded semaglutide and tirzepatide options are prescribed by licensed providers who integrate this comprehensive picture into your treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.